Clinical Trials Logo

Non-ischemic Cardiomyopathy clinical trials

View clinical trials related to Non-ischemic Cardiomyopathy.

Filter by:

NCT ID: NCT03509441 Recruiting - Diabetes Clinical Trials

Early MRI Detection of Myocardial Deterioration as a Preventive, Disease Staging, and Prognostic Biomarker in Insulin Resistance

Start date: January 15, 2015
Phase:
Study type: Observational

The purpose of this study is to evaluate the relationship between insulin resistance (IR) and myocardial tissue abnormalities. The study will focus on a patient population, South Asians, with a high prevalence of IR.

NCT ID: NCT03293381 Recruiting - Clinical trials for Non-ischemic Cardiomyopathy

Electrogram-Guided Myocardial Advanced Phenotyping

eMAP
Start date: November 30, 2016
Phase:
Study type: Observational

Fluoroscopy guided EMB and EAM guided EMB on all patients meeting existing guidelines for biopsy.

NCT ID: NCT03090425 Active, not recruiting - Clinical trials for Non Ischemic Cardiomyopathy

Inflammatory/Familial Dilated Cardiomyopathy: Is There a Link to Autoimmune Diseases? TP9a

Ikarius
Start date: June 2016
Phase:
Study type: Observational

In a hitherto ill-defined proportion of patients with inflammatory/familial cardiomyopathy, the phenotype dilative cardiomyopathy (DCM) is assumed to be the endstage of a multifactorial etiopathogenetic pathophysiology. Precipitating factors include enhanced autoimmunity, predisposition for viral infections, environmental factors in addition to a specific 'genetic background' of the individual patient. It is unresolved, whether the susceptibility to immunologically mediated myocardial damage reflects the presence of genetic risk factors shared by other autoimmune diseases, or is cardio-specific with individual predisposing factors. Aims of the project are the search for a genetic link or oredisposition to autoimmune diseases in patients with familial / inflammatory DCM.

NCT ID: NCT03071653 Recruiting - Clinical trials for Dilated Cardiomyopathy

Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study

LCSD
Start date: November 24, 2016
Phase: Phase 2
Study type: Interventional

A randomized controlled trial to test the potential safety and efficacy of LCSD in patients with heart failure due to non-ischemic and ischemic cardiomyopathy at the University of Cape Town. Left Cardiac Sympathetic Denervation (LCSD) is a surgical intervention that modulates the autonomic innervation of the cardiac system. This is important because: a] sympathetic and parasympathetic tone has a profound effect on the threshold for ventricular tachyarrhythmias-the main cause of sudden cardiac death in this population; and b] autonomic dysfunction (which is characterized by an imbalance between sympathetic and parasympathetic activation), plays an important detrimental role in the pathophysiology and progression of heart failure.

NCT ID: NCT02657967 Recruiting - Clinical trials for Non-ischemic Cardiomyopathy

Development of an Evidenced-Based Tool for Prediction of Sudden Death in Patients With Non-Ischemic Cardiomyopathy

NICMR
Start date: May 2015
Phase: N/A
Study type: Observational [Patient Registry]

This study is an observational study to determine predictors of sudden cardiac death or appropriate ICD therapy in patients with non-ischemic cardiomyopathy. Patients will be followed for 36 months for the occurrence of sudden cardiac death

NCT ID: NCT02346422 Terminated - Heart Failure Clinical Trials

A Phase 1/2 Study of High-dose Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

Start date: April 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this trial is to characterize the safety profile and preliminary activity of high-dose MYDICAR® in persons with advanced heart failure when added to their maximal and optimized therapy.

NCT ID: NCT01966887 Terminated - Clinical trials for Ischemic Cardiomyopathy

AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure

AGENT-HF
Start date: December 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effect of intracoronary SERCA2a Gene transfer on cardiac volumes and function using multimodality cardiac imaging.

NCT ID: NCT01935622 Terminated - Clinical trials for Non-ischemic Cardiomyopathy

Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy

DOXY-HF
Start date: July 2012
Phase: Phase 2
Study type: Interventional

Non-ischemic cardiomyopathy and heart failure are highly influenced by the presence of systemic inflammation. Doxycycline is a FDA-approved drug to treat bacterial infections which also shows powerful anti-inflammatory effects. In this study we plan to determine the effects of Doxycycline in patients with stable heart failure and non-ischemic cardiomyopathy on peak of aerobic exercise capacity (peak V02) and ventilator efficiency measured with a cardiopulmonary test.

NCT ID: NCT01914081 Recruiting - Clinical trials for Non-ischemic Cardiomyopathy

Resveratrol: a Potential Anti-remodeling Agent in Heart Failure, From Bench to Bedside

Start date: January 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if resveratrol can improve heart function and quality of life. Although, population studies have revealed that a mild to moderate intake of red wine reduces cardiovascular disease risk in humans, clinical studies that evaluate the potential heart benefits of resveratrol in patients with non-ischemic cardiomyopathy have not been previously reported. Accordingly, this research is being done because it will fill this deficiency in the information available in the literature and establish the clinical benefits of resveratrol in patients with this type of heart disease.

NCT ID: NCT01787851 Recruiting - Clinical trials for Congestive Heart Failure

Study of the Acute Effects of Triheptanoin in Heart Failure

ACETO-TCA
Start date: February 2013
Phase: Phase 1/Phase 2
Study type: Interventional

Patients with dilated cardiomyopathy who present for indwelling right heart catheterization will be enrolled and randomized to either control or triheptanoin oil for five days. Hemodynamics will be assess serially.